Background: CD134 (OX40) is a member of the tumor necrosis factor receptor superfamily that is expressed as a late event in T-cell activation and contributes to the generation of immunologic memory. CD134 blockade effectively ameliorates inflammation in models of autoimmune disease, but its role in transplantation has been less well studied.
Methods: The authors used an OX40-immunoglobulin (Ig) fusion protein to examine the contribution of this co-stimulatory molecule to the in vitro alloimmune response and studied the ability of CD134 blockade to prevent cardiac allograft rejection in mouse models of heart transplantation using strains representing both major histocompatibility complex (MHC) (BALB/c to CBA/Ca) and minor histocompatibility complex (mHC) (B10.BR to CBA/Ca) antigen mismatches.
Results: CD134 upregulation on in vitro alloactivated T cells was delayed compared with CD69 and CD25, and inhibition of T-cell proliferation was critically dependent on the timing of OX40-Ig administration. Heart allograft survival in a fully allogeneic, MHC-mismatched strain combination was not influenced by CD134 blockade alone, but OX40-Ig treatment in the mHC-mismatched model resulted in long-term graft survival (median survival time extended from 14 days to >100 days). Early mononuclear cell infiltration of the graft was similar in both rejecting and long-surviving heart grafts, but OX40-Ig treatment appeared to delay cellular infiltration.
Conclusions: These results show that CD134-CD134L interaction plays an important role in the co-stimulatory cascade and that blockade of this molecular interaction may be of therapeutic value in helping to prevent allograft rejection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.tp.0000131670.99000.54 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
Oncoimmunology
October 2024
Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, Hamburg, Germany.
Immune exhaustion is a hallmark of ovarian cancer. Using multiparametric flow cytometry, the study aimed to analyze protein expression of novel immunological targets on CD3 T cells isolated from the peripheral blood ( = 20), malignant ascites ( = 16), and tumor tissue ( = 6) of patients with ovarian cancer (OVCA). The study revealed an increased proportion of effector memory CD8 T cells in OVCA tissue and malignant ascites.
View Article and Find Full Text PDFChallenges and opportunities in the development of combination immunotherapy with OX40 agonists.
Expert Opin Biol Ther
November 2023
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Introduction: Costimulatory members of the tumor necrosis factor receptor family, such as OX40 (CD134), provide essential survival and differentiation signals that enhance T cell function. Specifically, OX40 (CD134) agonists stimulate potent anti-tumor immunity in a variety of preclinical models but their therapeutic impact in patients with advanced malignancies has been limited thus far.
Areas Covered: In this review, we discuss the current state of combination immunotherapy with OX40 agonists including preclinical studies and recent clinical trials.
The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
Front Immunol
March 2023
Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, China.
Article Synopsis
- - Bladder cancer (BLCA) is a severe type of tumor with poor survival rates; however, a combination therapy using oxaliplatin (OXP) and anti-PD-1 inhibitors shows promise for improving treatment response by reshaping the tumor's immune environment.
- - In a study using mice, results indicated that the combination of OXP and anti-PD-1 therapy led to greater tumor growth inhibition compared to using either treatment alone, with notable changes in immune cell infiltration in the tumors.
- - Flow cytometry analysis revealed that OXP enhanced the presence of various immune cells (like CD3, CD4, CD8 T cells, and dendritic cells), improving their function against the tumors, while maintaining
Current Clinical Trial Landscape of OX40 Agonists.
Curr Oncol Rep
July 2022
Earle A. Chiles Research Institute, Providence Cancer Institute, 4805 NE Glisan St., 2N35, Portland, OR, 97213, USA.
Purpose Of Review: Despite the efficacy of immune checkpoint blockade (ICB) immunotherapy, most cancer patients still develop progressive disease necessitating additional treatment options. One approach is ligation of the OX40 (CD134) costimulatory receptor which promotes T cell activation, effector function, and the generation of long-lived memory cells.
Recent Findings: Numerous preclinical studies have demonstrated that OX40 agonists alone or in combination with ICB (e.
IQGAP1 restrains T-cell cosignaling mediated by OX40.
FASEB J
January 2020
Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
A costimulatory signal from the tumor necrosis factor receptor (TNFR) family molecule OX40 (CD134), which is induced on activated T cells, is important for T-cell immunity. Aberrant OX40 cosignaling has been implicated in autoimmune and inflammatory disorders. However, the molecular mechanism by which the OX40 cosignaling regulates the T-cell response remains obscure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!